RecruitingNCT05160584

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma

Sponsor

Janssen Pharmaceutica N.V., Belgium

Enrollment

300 participants

Start Date

Nov 18, 2021

Study Type

OBSERVATIONAL

Conditions

Relapsed/Refractory Multiple Myeloma

Summary

The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking how people with relapsed or hard-to-treat multiple myeloma (a blood cancer affecting plasma cells) are managed in real-world clinical settings, including those starting a new drug called talquetamab. **You may be eligible if...** - You have a confirmed diagnosis of multiple myeloma - You are in good enough health (ECOG 0–2) - For one part of the study: you are starting treatment with talquetamab for relapsed/refractory multiple myeloma - You have received prior lines of therapy **You may NOT be eligible if...** - You are pregnant or planning to become pregnant during the study period - You are unable or unwilling to sign an informed consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

There is no interventional treatment component for participants with RRMM in this study.

Locations(87)

LKH Leoben

Leoben, Austria

Krankenhaus der barmherzigen Schwestern

Vienna, Austria

UZ Antwerpen

Edegem, Belgium

Ziekenhuis Oost-Limburg

Genk, Belgium

UZ Leuven

Leuven, Belgium

Chu Helora Hospital De Mons Site Kennedy

Mons, Belgium

Vitaz

Sint-Niklaas, Belgium

Ucl de Mont-Godinne

Yvoir, Belgium

CHRU de Lille Hopital Claude Huriez

Lille, France

CHU de Montpellier Hopital Saint Eloi

Montpellier, France

CHU de Nantes hotel Dieu

Nantes, France

Centre hospitalier Lyon-Sud

Pierre-Bénite, France

Pôle IUC Oncopole CHU

Toulouse, France

Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin

Berin, Germany

Universitaetsklinikum Koeln

Cologne, Germany

Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden

Dresden, Germany

Universitätsklinik Hamburg-Eppendorf - Orthopädische Universitätsklinik und Poliklinik

Hamburg, Germany

St. Barbara-Klinik Hamm GmbH

Hamm, Germany

Universitaetsklinikum Heidelberg

Heidelberg, Germany

Staedtisches Klinikum Karlsruhe gGmbH

Karlsruhe, Germany

MVZ Mitte-Onkologische Schwerpunktpraxis

Leipzig, Germany

Universitaetsklinikum Leipzig

Leipzig, Germany

Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany

Tübingen, Germany

Universitatsklinikum Wurzburg

Würzburg, Germany

Heinrich-Braun-Klinikum gGmbH

Zwickau, Germany

University Hospital of Alexandroupolis

Alexandroupoli, Greece

Henry Dunant Hospital Center

Athens, Greece

Laiko General Hospital Of Athens 1

Athens, Greece

Laiko General Hospital of Athens 2

Athens, Greece

Alexandra Hospital

Athens, Greece

Metaxa Cancer Center Hospital Of Piraeus

Piraeus, Greece

General University Hospital of Patras

Rio, Greece

Anticancer Hospital of Thessaloniki Theageneio

Thessaloniki, Greece

Ahepa University General Hospital of Thessaloniki

Thessaloniki, Greece

Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II

Bari, Italy

U.O. Ematologia Istituto Tumori Giovanni Paolo II

Bari, Italy

Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi

Bologna, Italy

Policlinico di Catania

Catania, Italy

Ospedale Civile di Civitanova Marche

Civitanova Marche, Italy

IRCCS Azienda Ospedaliera San Martino - IST

Genova, Italy

Ospedale Policlinico San Martino IRCCS

Genova, Italy

Ospedale Vito Fazzi

Lecce, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Meldola, Italy

Universita degli Studi di Padova Azienda Ospedaliera di Pa

Padova, Italy

Ospedale Villa Sofia-Cervello

Palermo, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Presidio Ospedaliero Pescara

Pescara, Italy

Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria

Reggio Calabria, Italy

Università di Roma La Sapienza

Roma, Italy

Fondazione Policlinico Universitario A Gemelli IRCCS

Roma, Italy

Campus Bio Medico di Roma

Roma, Italy

Casa Sollievo Della Sofferenza IRCCS

San Giovanni Rotondo, Italy

IRCCS Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo, Italy

Ospedale Cardinale G. Panico

Tricase, Italy

Azienda Ulss 8 Berica- Ospedale Di Vicenza

Vicenza, Italy

VU Medisch Centrum

Amsterdam, Netherlands

UMCG

Groningen, Netherlands

Ulstmad - Hosp. Chaves

Chaves, Portugal

Uls Coimbra - Hosp. Univ. Coimbra

Coimbra, Portugal

Uls Sao Joao - Hosp. Sao Joao

Porto, Portugal

Inst. Cat. Doncologia-H Duran I Reynals

Barcelona, Spain

Hosp. de Cabuenes

Gijón, Spain

Hosp. Univ. Virgen de Las Nieves

Granada, Spain

Hosp. de Jerez de La Frontera

Jerez de la Frontera, Spain

Hosp. de Leon

León, Spain

Hosp. Univ. Ramon Y Cajal

Madrid, Spain

Hosp. Univ. 12 de Octubre

Madrid, Spain

Hosp. Univ. Son Espases

Palma, Spain

Clinica Univ. de Navarra

Pamplona, Spain

Hosp Clinico Univ de Salamanca

Salamanca, Spain

Hosp. Univ. Marques de Valdecilla

Santander, Spain

Hosp. Clinico Univ. de Santiago

Santiago de Compostela, Spain

Hosp. Clinico Univ. de Valencia

Valencia, Spain

Hosp. Univ. Dr. Peset

Valencia, Spain

Hosp. Clinico Univ. de Valladolid

Valladolid, Spain

Hosp. Univ. Miguel Servet

Zaragoza, Spain

Kantonsspital Graubunden

Chur, Switzerland

Kantonsspital Winterthur, Medizinische Onkologie

Winterthur, Switzerland

Hirslanden Klinik Hirslanden

Zurich, Switzerland

Universitatsspital Zurich

Zurich, Switzerland

Southmead Hospital

Bristol, United Kingdom

University College Hospital

London, United Kingdom

Kings College Hospital

London, United Kingdom

St Georges Hospital

London, United Kingdom

Maidstone Hospital

Maidstone, United Kingdom

Nottingham University Hospitals NHS Trust

Nottingham, United Kingdom

The Royal Marsden NHS Trust Sutton

Surrey, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05160584

Related Trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT0497360583 locations

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT066692477 locations

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT0586201232 locations

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT0585023436 locations

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

NCT075090861 location